PTC Therapeutics, Inc. (PTCT) Net margin 2016–2025
PTC Therapeutics, Inc. (PTCT) net profit margin by fiscal year — reported net income divided by reported revenue.
39.4%FY2025 · since FY2016: -171.8% → 39.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 39.4% | +84.5 pp |
| FY2024 | -45.0% | +21.8 pp |
| FY2023 | -66.8% | +13.2 pp |
| FY2022 | -80.0% | +17.3 pp |
| FY2021 | -97.3% | +17.8 pp |
| FY2020 | -115.1% | -33.1 pp |
| FY2019 | -82.0% | -33.6 pp |
| FY2018 | -48.4% | -7.7 pp |
| FY2017 | -40.6% | +131.2 pp |
| FY2016 | -171.8% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More PTCT financial trends
PTCT RevenuePTCT Net incomePTCT Gross profitPTCT Gross marginPTCT Operating incomePTCT Operating marginPTCT Operating cash flowPTCT Free cash flowPTCT Capital expendituresPTCT Return on equityPTCT Stock buybacksPTCT Dividends paidPTCT Total assetsPTCT Total liabilitiesPTCT Shareholders’ equityPTCT overview →